Literature DB >> 30538135

CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.

David Martín-Garcia1,2, Alba Navarro1,2, Rafael Valdés-Mas3, Guillem Clot1,2, Jesús Gutiérrez-Abril3, Miriam Prieto1,2, Inmaculada Ribera-Cortada4, Renata Woroniecka5, Grzegorz Rymkiewicz6, Susanne Bens7,8, Laurence de Leval9, Andreas Rosenwald10,11, Judith A Ferry12, Eric D Hsi13, Kai Fu14,15, Jan Delabie16,17, Dennis Weisenburger18, Daphne de Jong19, Fina Climent20, Sheila J O'Connor21, Steven H Swerdlow22, David Torrents23,24, Sergi Beltran25, Blanca Espinet26,27, Blanca González-Farré2,28, Luis Veloza28, Dolors Costa2,28, Estella Matutes28, Reiner Siebert7,8, German Ott29,30, Leticia Quintanilla-Martinez31, Elaine S Jaffe32, Carlos López-Otín2,3, Itziar Salaverria1,2, Xose S Puente2,3, Elias Campo1,2,28,33, Sílvia Beà1,2.   

Abstract

Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation resulting in overexpression of cyclin D1. However, a small subset of cyclin D1- MCL has been recognized, and approximately one-half of them harbor CCND2 translocations while the primary event in cyclin D1-/D2- MCL remains elusive. To identify other potential mechanisms driving MCL pathogenesis, we investigated 56 cyclin D1-/SOX11+ MCL by fluorescence in situ hybridization (FISH), whole-genome/exome sequencing, and gene-expression and copy-number arrays. FISH with break-apart probes identified CCND2 rearrangements in 39 cases (70%) but not CCND3 rearrangements. We analyzed 3 of these negative cases by whole-genome/exome sequencing and identified IGK (n = 2) and IGL (n = 1) enhancer hijackings near CCND3 that were associated with cyclin D3 overexpression. By specific FISH probes, including the IGK enhancer region, we detected 10 additional cryptic IGK juxtapositions to CCND3 (6 cases) and CCND2 (4 cases) in MCL that overexpressed, respectively, these cyclins. A minor subset of 4 cyclin D1- MCL cases lacked cyclin D rearrangements and showed upregulation of CCNE1 and CCNE2. These cases had blastoid morphology, high genomic complexity, and CDKN2A and RB1 deletions. Both genomic and gene-expression profiles of cyclin D1- MCL cases were indistinguishable from cyclin D1+ MCL. In conclusion, virtually all cyclin D1- MCLs carry CCND2/CCND3 rearrangements with immunoglobulin genes, including a novel IGK/L enhancer hijacking mechanism. A subset of cyclin D1-/D2-/D3- MCL with aggressive features has cyclin E dysregulation. Specific FISH probes may allow the molecular identification and diagnosis of cyclin D1- MCL.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30538135      PMCID: PMC6396173          DOI: 10.1182/blood-2018-07-862151

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes.

Authors:  F Solé; B Espinet; M Salido; E Lloveras; C Fernández; J C Cigudosa; A Asensio; S Woessner; L Florensa
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

2.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.

Authors:  C Royo; A Navarro; G Clot; I Salaverria; E Giné; P Jares; D Colomer; A Wiestner; W H Wilson; M C Vegliante; V Fernandez; E M Hartmann; N Trim; W N Erber; S H Swerdlow; W Klapper; M J S Dyer; M Vargas-Pabón; G Ott; A Rosenwald; R Siebert; A López-Guillermo; E Campo; S Beà
Journal:  Leukemia       Date:  2012-03-19       Impact factor: 11.528

3.  In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Authors:  Erming Tian; Jeffrey R Sawyer; Christoph J Heuck; Qing Zhang; Frits van Rhee; Bart Barlogie; Joshua Epstein
Journal:  Genes Chromosomes Cancer       Date:  2014-03-17       Impact factor: 5.006

4.  Deregulated cyclin E induces chromosome instability.

Authors:  C H Spruck; K A Won; S I Reed
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

Review 5.  Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.

Authors:  Sílvia Beà; Virginia Amador
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

6.  Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking.

Authors:  Joachim Weischenfeldt; Taronish Dubash; Alexandros P Drainas; Balca R Mardin; Yuanyuan Chen; Adrian M Stütz; Sebastian M Waszak; Graziella Bosco; Ann Rita Halvorsen; Benjamin Raeder; Theocharis Efthymiopoulos; Serap Erkek; Christine Siegl; Hermann Brenner; Odd Terje Brustugun; Sebastian M Dieter; Paul A Northcott; Iver Petersen; Stefan M Pfister; Martin Schneider; Steinar K Solberg; Erik Thunissen; Wilko Weichert; Thomas Zichner; Roman Thomas; Martin Peifer; Aslaug Helland; Claudia R Ball; Martin Jechlinger; Rocio Sotillo; Hanno Glimm; Jan O Korbel
Journal:  Nat Genet       Date:  2016-11-21       Impact factor: 38.330

7.  Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.

Authors:  E Frei; C Visco; Z Y Xu-Monette; S Dirnhofer; K Dybkær; A Orazi; G Bhagat; E D Hsi; J H van Krieken; M Ponzoni; R S Go; M A Piris; M B Møller; K H Young; A Tzankov
Journal:  J Clin Pathol       Date:  2013-06-17       Impact factor: 3.411

8.  Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Authors:  Maurizio Scaltriti; Pieter J Eichhorn; Javier Cortés; Ludmila Prudkin; Claudia Aura; José Jiménez; Sarat Chandarlapaty; Violeta Serra; Aleix Prat; Yasir H Ibrahim; Marta Guzmán; Magui Gili; Olga Rodríguez; Sonia Rodríguez; José Pérez; Simon R Green; Sabine Mai; Neal Rosen; Clifford Hudis; José Baselga
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

9.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

Authors:  Sílvia Beà; Rafael Valdés-Mas; Alba Navarro; Itziar Salaverria; David Martín-Garcia; Pedro Jares; Eva Giné; Magda Pinyol; Cristina Royo; Ferran Nadeu; Laura Conde; Manel Juan; Guillem Clot; Pedro Vizán; Luciano Di Croce; Diana A Puente; Mónica López-Guerra; Alexandra Moros; Gael Roue; Marta Aymerich; Neus Villamor; Lluís Colomo; Antonio Martínez; Alexandra Valera; José I Martín-Subero; Virginia Amador; Luis Hernández; Maria Rozman; Anna Enjuanes; Pilar Forcada; Ana Muntañola; Elena M Hartmann; María J Calasanz; Andreas Rosenwald; German Ott; Jesús M Hernández-Rivas; Wolfram Klapper; Reiner Siebert; Adrian Wiestner; Wyndham H Wilson; Dolors Colomer; Armando López-Guillermo; Carlos López-Otín; Xose S Puente; Elías Campo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

10.  A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Authors:  Guillem Clot; Pedro Jares; Eva Giné; Alba Navarro; Cristina Royo; Magda Pinyol; David Martín-Garcia; Santiago Demajo; Blanca Espinet; Antonio Salar; Ana Ferrer; Ana Muntañola; Marta Aymerich; Hilka Rauert-Wunderlich; Elaine S Jaffe; Joseph M Connors; Randy D Gascoyne; Jan Delabie; Armando López-Guillermo; German Ott; George W Wright; Louis M Staudt; Andreas Rosenwald; David W Scott; Lisa M Rimsza; Sílvia Beà; Elías Campo
Journal:  Blood       Date:  2018-05-16       Impact factor: 25.476

View more
  26 in total

1.  Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies.

Authors:  Jess F Peterson; Linda B Baughn; Rhett P Ketterling; Beth A Pitel; Stephanie A Smoley; George Vasmatzis; James B Smadbeck; Patricia T Greipp; Abhishek A Mangaonkar; Carrie A Thompson; Sameer A Parikh; Dong Chen; David S Viswanatha
Journal:  Blood Adv       Date:  2019-04-23

Review 2.  Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.

Authors:  Michael J Buege; Anita Kumar; Brianne N Dixon; Laura A Tang; Terry Pak; Jennifer Orozco; Tim J Peterson; Kathryn T Maples
Journal:  Ann Pharmacother       Date:  2020-02-20       Impact factor: 3.154

3.  Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.

Authors:  Ferran Nadeu; David Martin-Garcia; Guillem Clot; Ander Díaz-Navarro; Martí Duran-Ferrer; Alba Navarro; Roser Vilarrasa-Blasi; Marta Kulis; Romina Royo; Jesús Gutiérrez-Abril; Rafael Valdés-Mas; Cristina López; Vicente Chapaprieta; Montserrat Puiggros; Giancarlo Castellano; Dolors Costa; Marta Aymerich; Pedro Jares; Blanca Espinet; Ana Muntañola; Inmaculada Ribera-Cortada; Reiner Siebert; Dolors Colomer; David Torrents; Eva Gine; Armando López-Guillermo; Ralf Küppers; Jose I Martin-Subero; Xose S Puente; Sílvia Beà; Elias Campo
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

Review 4.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

Review 5.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

6.  Genome-wide detection of enhancer-hijacking events from chromatin interaction data in rearranged genomes.

Authors:  Xiaotao Wang; Jie Xu; Baozhen Zhang; Ye Hou; Fan Song; Huijue Lyu; Feng Yue
Journal:  Nat Methods       Date:  2021-06-03       Impact factor: 28.547

Review 7.  Tales from topographic oceans: topologically associated domains and cancer.

Authors:  Moray J Campbell
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

8.  Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma.

Authors:  Carla Fuster; David Martín-Garcia; Olga Balagué; Alba Navarro; Ferran Nadeu; Dolors Costa; Miriam Prieto; Itziar Salaverria; Blanca Espinet; Alfredo Rivas-Delgado; Maria José Terol; Eva Giné; Pilar Forcada; Margaret Ashton-Key; Xose S Puente; Steven H Swerdlow; Sílvia Beà; Elias Campo
Journal:  Haematologica       Date:  2019-11-21       Impact factor: 9.941

9.  SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma.

Authors:  Shashidhar S Jatiani; Stephanie Christie; Violetta V Leshchenko; Rinku Jain; Abhijeet Kapoor; Paola Bisignano; Clement Lee; H Ümit Kaniskan; Donna Edwards; Fanye Meng; Alessandro Laganà; Youssef Youssef; Adrian Wiestner; Lapo Alinari; Jian Jin; Marta Filizola; Aneel K Aggarwal; Samir Parekh
Journal:  Clin Cancer Res       Date:  2021-06-22       Impact factor: 12.531

Review 10.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.